Obstetrics, gynecology and reproductive medicine guidelines

Hepatitis

PubMed Free Full Text

Hepatitis C: treatment

 

Albania

• Virology Journal
  • Treatment and follow up of children with chronic hepatitis C in Albania [2012]

Asia, Pacific

• Asian Pacific Association for the Study of the Liver
  • APASL consensus statements and recommendation on treatment of hepatitis C [2016]

• Journal of Virus Eradication
  • The hepatitis C treatment revolution: how to avoid Asia missing out [2015]

Australia

• Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine
  • HCV Treatments Quick Reference Tool [2017]

• Australian Family Physician
  • A practical overview of the treatment of chronic hepatitis C virus infection [2016]

• Australian Journal of General Practice
  • Insights into the management of chronic hepatitis C [2018]

• Australian Prescriber
  • Treating hepatitis C – what’s new? [2015]

• ClinicoEconomics and Outcomes Research
  • The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia [2017]

• SA Health
  • Hepatitis C community prescribing

• UNSW - The Kirby Institute for infection and immunity in society
  • Real world efficacy of antiviral therapy in chronic hepatitis C (REACH-C) in Australia [2017]
  • Monitoring hepatitis C treatment uptake in Australia [2017]

Australia, New Zealand

• Australasian Hepatology Association
  • The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals [2016]

Brazil

• BMC Public Health
  • The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy [2016]

• Brazilian Journal of Infectious Diseases
  • Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil [2018]

• Ciência & Saúde Coletiva
  • Public procurement of hepatitis C medicines in Brazil from 2005 to 2015 [2017]

• Cost Effectiveness and Resource Allocation
  • Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil [2013]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • Drugs for Chronic Hepatitis C Infection: Cost-Effectiveness Analysis [2016]
  • Drugs for Chronic Hepatitis C Infection: Clinical Review [2016]
  • Ledipasvir/Sofosbuvir (Harvoni): For the Treatment of Chronic Hepatitis C Virus (CHC) G1 Infection in Adults [2015]
  • Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence [2015]
  • Drugs for Chronic Hepatitis C Infection: Recommendations Report [2015]
  • Triple Therapy for Hepatitis C in Previous Non-responders: A Review of the Clinical Effectiveness and Safety [2014]
  • Treatments for Patients with Genotype 1 Chronic Hepatitis C: A Review of Evidence-based Guidelines [2014]
  • Interferon-free Regimens for Genotype 1 Chronic Hepatitis C: A Review of the Clinical Evidence and Cost-Effectiveness [2014]

• Canadian Association for the Study of the Liver
  • The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver [2018]
  • An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver [2015]

• Canadian Journal of Gastroenterology & Hepatology
  • Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: A policy statement and implementation guideline [2014]

• CMAJ Open
  • Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis [2017]
  • Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study [2016]

• PLoS ONE
  • Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? [2015]

China

• PLoS ONE
  • Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data [2016]

• World Journal of Gastroenterology
  • Current treatment of chronic hepatitis C in China: Dilemma and potential problems [2016]

Egypt

• Alimentary Pharmacology & Therapeutics
  • Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies [2015]

Europe

• BMC Infectious Diseases
  • Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries [2014]
  • A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region [2014]

• BMC Public Health
  • Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe [2019]

• European Association for the Study of the Liver
  • EASL Recommendations on Treatment of Hepatitis C 2018 [2018]
  • Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015 [2015]

• European Society for Paediatric Gastroenterology Hepatology and Nutrition
  • Guidance for Clinical Trials for Children and Adolescents With Chronic Hepatitis C [2011]

• Frontiers in Pharmacology
  • Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future [2016]

• Harm Reduction Journal
  • Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries [2019]

• WHO Regional Office for Europe
  • Barriers and facilitators to hepatitis C treatment for people who inject drugs. A qualitative study [2012]

France

• BMC Infectious Diseases
  • Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015 [2017]

Germany

• BMC Infectious Diseases
  • Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach [2015]

• BMJ Open Gastroenterology
  • Economic study of the value of expanding HCV treatment capacity in Germany [2017]

• Institute for Quality and Efficiency in Health Care
  • Glecaprevir/pibrentasvir (chronic hepatitis C) – Benefit assessment according to § 35a Social Code Book V [2017]
  • Elbasvir/grazoprevir (chronic hepatitis C) - Benefit assessment according to §35a Social Code Book V [2017]

• PLoS ONE
  • Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany [2017]
  • Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study [2016]

• Visceral Medicine
  • The New Era of Interferon-Free Treatment of Chronic Hepatitis C [2015]

India

• Journal of Clinical and Experimental Hepatology
  • Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015 [2015]

International

• Autoimmune Diseases
  • International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement [2017]

• Bulletin of the World Health Organization
  • Treatment of people diagnosed with chronic hepatitis C virus infection [2018]
  • Access to hepatitis C medicines [2015]

• Clinical Pharmacology & Therapeutics
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-a–Based Regimens [2014]

• Forum for Collaborative HIV Research
  • Hepatitis C virus drug resistance–associated substitutions: State of the art summary [2015]
  • Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy [2013]
  • Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents [2012]
  • Clinically Relevant HCV Drug Resistance Mutations Figure and Tables [2012]

• PLoS Medicine
  • Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis [2016]

• Scientific Reports
  • Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data [2016]

Italy

• ClinicoEconomics and Outcomes Research
  • Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service [2017]
  • Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives [2016]

• Digestive and Liver Disease
  • Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) [2013]

Japan

• Drug Design, Development and Therapy
  • Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study [2016]

• Journal of Gastroenterology
  • Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines [2013]

• Viruses
  • HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy [2015]

• World Journal of Hepatology
  • Natural interferon-beta treatment for patients with chronic hepatitis C in Japan [2015]

Latin America

• Annals of Hepatology
  • Latin American Association for the Study of the Liver recommendations on treatment of hepatitis C [2014]

Low and middle-income countries

• Bulletin of the World Health Organization
  • Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis [2012]

• Treatment Action Group
  • Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries [2015]

• World Health Organization
  • Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries [2018]

Netherlands

• Netherlands Journal of Medicine
  • Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era [2014]
  • Treatment of hepatitis C monoinfection in adults--Dutch national guidelines [2013]

• PLoS ONE
  • Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study [2016]

Pakistan

• Asian Pacific Journal of Tropical Medicine
  • Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective [2015]

• BMJ Open
  • Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections [2019]

Poland

• Clinical and Experimental Hepatology
  • Recommendations for the treatment of hepatitis C in 2017 [2017]
  • Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study [2016]

• Przeglad Epidemiologiczny - Epidemiological Review
  • Recommendations for the treatment of hepatitis C Polish group of HCV Experts--2015 [2015]
  • Standards of hepatitis C treatment. Recommendations of Polish Group of Experts--2014 [2014]

Republic of Korea

• Clinical and Molecular Hepatology
  • Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL [2018]

• Korean Association for the Study of the Liver
  • 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C [2018]

Romania

• Journal of Gastrointestinal and Liver Diseases
  • Position paper on treatment of hepatitis C in Romania, 2017. Part one [2017]
  • Position Paper on Treatment of Hepatitis C in Romania 2017. Part Two [2017]

Saudi Arabia

• Saudi Journal of Gastroenterology
  • SASLT guidelines: Update in treatment of Hepatitis C virus infection [2016]

Singapore

• Ministry of Health Singapore
  • Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C [2018]

Spain

• Health Policy
  • The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain - Health Policy [2016]

• Revista Española de Sanidad Penitenciaria
  • Treatment guidelines for Hepatitis C in Spain [2015]

Sweden

• Infectious Diseases
  • Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations [2015]

Switzerland

• PLoS ONE
  • Drug Pricing Evolution in Hepatitis C [2016]
  • Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C [2015]

Taiwan

• Journal of the Formosan Medical Association
  • Hepatitis C virus infection in Taiwan: Past, present, and future [2016]

• Kaohsiung Journal of Medical Sciences
  • A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan [2017]

• Medicine
  • Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C [2015]

Thailand

• BMC Gastroenterology
  • Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6 [2016]

• PLoS ONE
  • Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era [2016]

Turkey

• Balkan Medical Journal
  • Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study [2016]

• Turkish Journal of Gastroenterology
  • Recommendation for treatment of hepatitis C virus infection [2017]

United Kingdom

• Alimentary Pharmacology & Therapeutics
  • 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy [2014]

• Health Protection Scotland
  • National Clinical Guidelines for the treatment of HCV in adults [2018]

• Health Technology Assessment
  • The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation [2014]

• Medicines and Healthcare products Regulatory Agency
  • Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR [2017]
  • Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation [2017]

• National Institute for Health and Care Excellence
  • Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C [2018]
  • Glecaprevir–pibrentasvir for treating chronic hepatitis C [2018]
  • Sofosbuvir–velpatasvir for treating chronic hepatitis C [2017]
  • Elbasvir–grazoprevir for treating chronic hepatitis C [2016]
  • Sofosbuvir for treating chronic hepatitis C [2015]
  • Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C [2015]
  • Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C [2015]
  • Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C [2015]
  • Ledipasvir–sofosbuvir for treating chronic hepatitis C [2015]
  • Daclatasvir for treating chronic hepatitis C [2015]
  • Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people [2013]
  • Telaprevir for the treatment of genotype 1 chronic hepatitis C [2012]
  • Boceprevir for the treatment of genotype 1 chronic hepatitis C [2012]
  • Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C [2010]

• NHS England
  • Treatment of chronic Hepatitis C in patients with cirrhosis [2015]

• PLoS ONE
  • Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections [2015]

• Public Health England
  • Antiviral resistance testing in the management of hepatitis C

United States of America

• Agency for Healthcare Research and Quality
  • Treatment for Hepatitis C Virus Infection in Adults [2013]
  • Comparative Effectiveness of Treatments for Chronic Hepatitis C Virus Infection in Adults [2012]

• American Association for the Study of Liver Diseases
  • An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases [2011]
  • Retreatment of Persons in Whom Prior Therapy Failed
  • Initial Treatment of HCV Infection

• American Gastroenterological Association
  • American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection [2017]

• American Journal of Managed Care
  • Costs and Spillover Effects of Private Insurers’ Coverage of Hepatitis C Treatment [2016]
  • Accessing the Cure: Helping Patients With Hepatitis C Overcome Barriers to Care [2016]

• BMC Gastroenterology
  • Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US [2015]

• Infectious Agents and Cancer
  • Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States [2016]

• Infectious Diseases and Therapy
  • Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need [2016]

• Liver International
  • HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape [2015]

• North American Journal of Medical Sciences
  • Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies [2016]

• Open Forum Infectious Diseases
  • The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets [2018]

• PLoS ONE
  • The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis [2014]

• U.S. Department of Veterans Affairs
  • A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System [2014]
  • Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C [2013]

WHO

• World Health Organization
  • Global report on access to hepatitis C treatment - Focus on overcoming barriers [2016]

{Related topics}

• Guidelines
  • Hepatitis C